A Phase II Study of Modified FOLFOX4 for Colorectal Cancer Patients with Peritoneal Carcinomatosis.
- Author:
Dong Hyun LEE
1
;
Sung Yong OH
;
Yu Rim LEE
;
Seok Jae HUH
;
Hyun Hwa YOON
;
Sung Hyun KIM
;
Suee LEE
;
Ji Hyun LEE
;
Young KIM
;
Hyo Jin KIM
;
Hyuk Chan KWON
Author Information
1. Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea. hckwon@dau.ac.kr
- Publication Type:Original Article
- Keywords:
Colorectal neoplasms;
Peritoneum;
Carcinoma;
Drug therapy
- MeSH:
Carcinoembryonic Antigen;
Carcinoma;
Cause of Death;
Colorectal Neoplasms;
Fluorouracil;
Humans;
Leucovorin;
Liver;
Neoplasm Metastasis;
Organoplatinum Compounds;
Peritoneum
- From:Cancer Research and Treatment
2011;43(4):225-230
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Peritoneal carcinomatosis (PC) of colorectal cancer (CRC) is common and is the second most common cause of death. Clinical studies regarding chemotherapy for CRC with PC have been classically rather limited in scope. We evaluated the efficacy of modified oxaliplatin, leucovorin, and fluorouracil (m-FOLFOX4) regimen for PC of CRC origin. MATERIALS AND METHODS: CRC patients with PC were treated with cycles of oxaliplatin at 85 mg/m2 on day 1, leucovorin 20 mg/m2 followed by 5-fluorouracil (5-FU) via a 400 mg/m2 bolus and a 22 hours continuous infusion of 600 mg/m2 5-FU on days 1-2 at 2-week intervals. RESULTS: Forty patients participated in this study. Median age was 55 years. Thirty-two patients (80.0%) received previous operation, and 60.0% of PC occurred synchronously. Thirty-five patients (87.5%) were assessable and exhibited measurable lesions. Two patients (5.7%) demonstrated complete response and five patients (14.3%) showed partial response. The median time to progression was 4.4 months (95% confidence interval, 2.5 to 6.3 months), the median overall survival time was 21.5 months (95% confidence interval, 17.2 to 25.7 months). There was no treatment related death. Presence of liver metastasis (p=0.022), performance status (p=0.039), and carcinoembryonic antigen level (p=0.016) were related to the time to progression. Patients with low carcinoembryonic antigen level (37.2 months vs. 15.6 months, p=0.001) or good performance status (22.5 months vs. 6.8 months, p=0.040) showed better overall survival. CONCLUSION: The m-FOLFOX4 regimen was determined to be effective for CRC patients with PC.
